PATENT CLAIM ANALYSIS

Application Number: 16196789
Application Type: Utility
Filing Date: 2018-11
Publication Date: 2019-03
Patent Classification: ["546", "062000"]

Abstract:
The present application relates to securinine or norsecurinine analogues that, when administered to immature myeloid cells, promote differentiation of these cells to mature cells that do not readily proliferate. Therefore, the agents are useful in the treatment of myeloid disorders including myeloproliferative disorders, acute myeloid leukemia, and autoimmune diseases. The agents may also be used as a myeloablative agent in conjunction with a bone marrow transplant or stem cell therapy.

Claim (Index 100):
The method of  claim 96 , wherein the securinine or norsecurinine analogue is selected from: or pharmaceutically acceptable salts thereof.

Metadata:
- Claim Count in Document: 39.0
- Percentile: 98.0
- Lexical Diversity: 1.36842
- Patent Class: 546.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15026916', '14029066', '15262902', '15029943', '15347587']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7745514896806749
- 35 USC 102 Novelty (BERT): 0.6700273216828856
- Combined Prediction Score: 0.764099072880896
- Mean Citation Score: 429.574716
- Max Citation Score: 764.2011
- Similarity Product: 613.5552116836129

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test